PR Newswire Clinical TrialsOriginal article
Pyrotech Therapeutics Doses First Subject in Phase 1 Study of PTT-121, the World's First Selective GSDMD Inhibitor to Enter Clinical Development
Phase 1PTT-121Positive
AI Analysis
Summary
Pyrotech Therapeutics announced dosing of the first subject in a Phase 1 clinical trial of PTT-121, described as the world's first selective GSDMD inhibitor to enter clinical development. This milestone validates the company's platform approach for targeting previously undruggable biological mechanisms.
Clinical Trial Data
Phase
Phase 1
Outcome Details
First subject dosed in Phase 1 study
Importance:6/10
Sentiment:
0.70
Phase 1Clinical milestoneFirst-in-classGSDMD inhibitorPyroptosisInnate immune modulation
Read the original article
Published by PR Newswire Clinical Trials on September 1, 2026 12:00 PM